BioCentury
ARTICLE | Clinical News

Omeros to start Phase III trial of OMS721 to treat IgA nephropathy

January 5, 2018 10:19 PM UTC

Omeros Corp. (NASDAQ:OMER) said it reached an agreement with FDA on the design of a Phase III trial to test OMS721 in patients with IgA nephropathy. The company expects to begin enrollment early February.

The double-blind, placebo-controlled trial will enroll patients with 24-hour urine protein excretion of more than 1 g/day who are on optimized renin-angiotensin system blockade. Patients will receive 12 IV doses of OMS721 once weekly, with additional weekly dosing permitted for partial responders and relapsers...

BCIQ Company Profiles

Omeros Corp.